J&J halts cancer combo trial

May 29, 2018

Johnson and Johnson’s Janssen has decided to halt its study involving blockbuster cancer drug, Darzalex.

The trial end announcement was made by Danish biotech, Genmab, who granted Janssen an exclusive worldwide license to develop, manufacture and commercialize daratumumab in August 2012,.

Janssen had been testing Darzalex plus atezolizumab, marketed by Roche as Tecentriq, in patients with previously treated non-small cell lung cancer.

Darzalex, approved in Nov 2015, has been a key treatment in multiple myeloma. It’s potential to treat solid tumors has been highly anticipated — making this trial failure a disappointment for both companies.

The trial announcement was made by Genmab, who granted Janssen an exclusive worldwide license to develop, manufacture and commercialize daratumumab in August 2012,.

Show Comments
Hide Comments

Join the discussion

We welcome your thoughtful comments.
All comments will display your user name.

Want to participate in the discussion?

Register for free

Log in for complete access.

Comments

No one has commented on this page yet.

RSS feed for comments on this page | RSS feed for all comments